Patent · US Active

Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors

US7592346B2 · kind B2 · utility

0Cited by

15References

25Claims

0Family size

Assignee

Glaxo Group Limited · GB

Inventors

Markus Bergauer · Verona, IT
Barbara Bertani · Castiglione delle Stiviere, IT
Matteo Biagetti · Verona, IT
Steven Mark Bromidge · Sawbridgeworth, GB
Alessandro Falchi · Sassari, IT
Colin Philip Leslie · Verona, IT
Giancarlo Merlo · Verona, IT
Domenica Antonia Pizzi · Verona, IT
Marilisa Rinaldi · Verona, IT
Luigi Piero Stasi · Verona, IT
Jessica Tibasco · Verona, IT
Antonio Kuok Keong Vong · Warrenpoint, GB
Simon Edward Ward · Peacehaven, GB

Key dates

Filing date	Jul 2, 2008
Grant date	Sep 22, 2009
Priority date	—
Expiry date	Jul 2, 2028

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC04B35/632
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are methods for use of compounds of formula (I) in combination with other active substances in the treatment of CNS disorders such as depression or anxiety.wherein R1, m, X, R2, n, W, p, Y, Z, R3, R4, R5 and q have the meanings as defined in the description.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.